Autoimmune Encephalitis future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis research is evaluating targeted immune treatments for patients with incomplete response to conventional therapy. Investigational treatment should be distinguished from established first- and second-line approaches. Published recommendations support specialist reassessment before rescue treatment because persistent disability does not necessarily represent ongoing immune activity.[1]
Future or Investigational Therapies
B-Cell-Directed Treatment
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies is being studied in the ExTINGUISH trial of inebilizumab, which targets cluster of differentiation 19 (CD19)-expressing B-lineage cells. The published phase 2b randomized, placebo-controlled protocol evaluates treatment in addition to first-line care and includes clinical, cognitive, quality-of-life, and biomarker outcomes. A protocol describes planned methods rather than proving efficacy.[2]
Interleukin-6 Receptor Blockade
Autoimmune encephalitis research includes satralizumab, an interleukin-6 (IL-6) receptor inhibitor. The phase 3 CIELO study evaluates it in NMDAR antibody encephalitis and leucine-rich glioma-inactivated protein 1 (LGI1) antibody encephalitis. The sponsor's study summary describes randomized comparison with placebo and functional and safety outcomes.[3]
Autoimmune encephalitis refractory to conventional treatment has also been treated with tocilizumab, another IL-6 receptor inhibitor. Supporting evidence has largely involved observational experience; it is not a routine first-line treatment.[1]
Plasma-Cell-Directed Treatment
Autoimmune encephalitis research includes bortezomib, a proteasome inhibitor targeting antibody-producing plasma cells. GENERATE-BOOST is a randomized, placebo-controlled phase 2 trial in severe disease. Trial registration should not be interpreted as evidence of benefit.[4]
Autoimmune encephalitis is also being investigated with combined B-cell and plasma-cell targeting. The 2026 RADIA protocol compares ofatumumab, targeting cluster of differentiation 20 (CD20), followed by daratumumab, targeting cluster of differentiation 38 (CD38), with comparator regimens. Planned outcomes include disability, cognition, hospitalization, and safety. This publication is a trial protocol, not an efficacy report.[5]
Neonatal Fc Receptor Antagonism
Autoimmune encephalitis studies are evaluating efgartigimod, which blocks the neonatal Fc receptor (FcRn) and reduces recycling of immunoglobulin G (IgG). A small 2026 retrospective cohort of 15 patients reported improvement associated with treatment. Without a control group, it cannot establish causation or comparative effectiveness.[6]
Interpretation and Safety
Autoimmune encephalitis investigational evidence must be interpreted according to study design. Uncontrolled improvement may reflect concurrent immunotherapy, natural recovery, or selection bias. Small cohorts cannot reliably exclude uncommon or delayed adverse effects.[6]
Autoimmune encephalitis rescue treatment requires review of diagnosis, previous treatment adequacy, infection, and associated neoplasm. Additional immunosuppression carries treatment-specific risks and should be managed through experienced specialist teams.[1]
Future Research Priorities
Autoimmune encephalitis trials should evaluate cognition, quality of life, and meaningful functional recovery alongside global disability. ExTINGUISH incorporates these outcomes and biofluid studies to investigate treatment response and disease biology.[2] Important unanswered questions include which subtypes benefit, optimal timing, treatment duration, relapse prevention, and long-term safety.
Clinical Trial Information
Autoimmune encephalitis trial eligibility and recruitment status change over time and may differ by country or site. Consult the linked registry records and treating specialist for current information. This chapter summarizes research available on November 6, 2026; listed therapies should not be treated as interchangeable or automatically appropriate for an individual patient.
Related Chapters
References
- ↑ 1.0 1.1 1.2 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.
- ↑ 2.0 2.1 A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial. Neurol Open Access. 2025;1(2):e000007. doi:10.1212/WN9.0000000000000007. PMID:40625668. Trial registration: NCT04372615.
- ↑ Genentech. Phase III: Satralizumab in NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis (Cielo). Trial registration: NCT05503264. Accessed November 6, 2026.
- ↑ ClinicalTrials.gov. Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (Generate-Boost). NCT03993262. See also German Clinical Trials Register: DRKS00017497. Accessed November 6, 2026.
- ↑ Xie W, Zhang LJ, Yue C, et al. Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial. Front Neurol. 2026;17:1783651. doi:10.3389/fneur.2026.1783651. PMID:42293080. Trial registration: NCT06867991.
- ↑ 6.0 6.1 The Clinical Efficacy and Safety of Efgartigimod in the Treatment of Autoimmune Encephalitis. Immunol Invest. 2026. PMID:42159021.